Gaithersburg, MD, August 23, 2001 -- MedImmune, Inc. (Nasdaq: MEDI) announced today six recent promotions and new appointments. MedImmune promoted W. Ripley Ballou, Jr. M.D. to vice president and group leader, clinical research, David A. Carlin, Ph.D. to vice president and group leader, biostatistics and data management, and Robert H. Earhart, Jr., M.D., Ph.D. to vice president, clinical research. In addition, Jeffrey S. Hackman has joined MedImmune as vice president, marketing, Peter A. Kiener, D.Phil. is joining as vice president, research, and Peter A. Patriarca, M.D. has joined as vice president, regulatory affairs.
"MedImmune has grown tremendously over the past several years and it is gratifying to be able to recognize the growth in leadership within the organization through the promotions of Drs. Ballou, Carlin and Earhart," said David M. Mott, chief executive officer. "It is also important to selectively infuse the team with new talent from time to time. Mr. Hackman and Drs. Kiener and Patriarca bring outstanding skills and unique experience bases to our organization. We are counting on each of these exceptional individuals to lead our future growth."
Rip Ballou joined MedImmune in 1999 as director of clinical research after 19 years at Walter Reed Medical Center and Institute of Research where he held a number of progressively responsible positions, departing as chief of the department of immunology in the Division of Communicable Diseases and Immunology. In 1988, Dr. Ballou co-founded and became president and chief scientific officer of Univax Biologicals, a biotechnology company in Rockville, Maryland. He was also an adjunct professor of research at the University of Virginia School of Medicine from 1997 to 1999. Dr. Ballou has authored or co-authored over a 114 publications and submitted 12 new drug applications. Dr. Ballou earned his medical degree from Emory University School of Medicine and his bachelor of science degree from the Georgia Institute of Technology.
Dave Carlin joined MedImmune in 1995 as director biostatistics and data management. Before coming to MedImmune, he was director of biostatistics and data/information systems for Otsuka America Pharmaceutical, Inc. from 1991 to 1995, and from 1985 to 1991 he was employed at Cetus Corporation as director, clinical research and development. Dr. Carlin had previously been a statistician at Warner-Lambert/Parke-Davis, a lecturer at Golden State University, a visiting scholar in the department of biostatistics at the University of North Carolina and a research specialist at the Arizona Cancer Center. He has authored or co-authored over a dozen peer-reviewed publications. Dr. Carlin received his Ph.D. and master's degree in experimental psychology at the Illinois Institute of Technology, and his bachelor of science degree from Drake University.
Bob Earhart came to MedImmune in 1999 as senior director, clinical research. From 1995 to 1999, Dr. Earhart was the associate director, oncology medical affairs at Rhône Poulenc Rorer Pharmaceuticals, Inc., prior to which he had a 13-year career at The Upjohn Company where he held a number of increasingly responsible positions, departing as the associate clinical research director. Dr. Earhart has taught at a number of institutions, including the University of Michigan, University of Wisconsin and Wayne State University and been on the hospital staff of the University of Michigan Hospital and Clinics, the University of Wisconsin Hospital, and the Bronson and Borgess Hospitals in Kalamazoo, Michigan. He has been a reviewer for a number of leading peer-review journals, appointed to several national, international and state boards and committees, and authored several dozen abstracts, publications, review articles, book chapters and educational materials. He received his M.D., Ph.D. and bachelor's degrees from Northwestern University.
Jeff Hackman joins MedImmune from Aventis Pasteur, Inc. where he held a number of marketing positions since 1994, most recently holding the title of director of marketing with responsibility for product management, market research, analytical services and marketing communications. During his tenure, sales of the portfolio of infectious disease and pediatric vaccine products for which he had responsibility increased over three-fold to $700 million. Prior to Aventis, Mr. Hackman spent eight years with Lederle Laboratories, holding various sales and marketing positions. He completed his bachelor of arts degree at Lycoming College.
Peter Kiener is joining MedImmune after 17 years with Bristol Myers Squibb (BMS), most recently holding the title of director, immunology, inflammation, and pulmonary drug discovery. Prior to joining BMS, he was an anatomy professor at the University of North Texas and a research associate in biochemistry at the University of Massachusetts, after having completed his post-doctoral research at the University of Oxford. He has authored or co-authored 67 publications. Dr. Kiener received a D.Phil. in biochemistry from University of Oxford and a bachelor of science degree from Lancaster University.
Peter Patriarca comes to MedImmune from the U.S. Food and Drug Administration where he most recently was director, division of viral products in the Office of Vaccines Research & Review in the Center for Biologics Evaluation & Research (CBER). Prior to joining the CBER in 1994, he held a number of progressively responsible positions with the Center for Disease Control for 13 years. Patriarca has also served as an officer in the U.S. Public Health Service for 20 years and has held academic appointments with Emory University and Johns Hopkins University. He is board certified in pediatrics, and has completed residencies in pediatrics and preventative medicine. He has also published nearly 100 peer-reviewed manuscripts. Patriarca received his medical degree from Tulane University School of Medicine and his bachelor's degree from the University of Notre Dame.
MedImmune, Inc. is a biotechnology company focused on developing and marketing products that address medical needs in areas such as infectious disease, immune regulation and cancer. Headquartered in Gaithersburg, Maryland, MedImmune has manufacturing facilities in Frederick, Maryland and Nijmegen, the Netherlands.
This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in the company's filings with the U.S. Securities and Exchange Commission. The company is developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.